61 tracked 13F filers disclose a position in CBIO as of the latest SEC 13F filings, a combined $468.0M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $75.9M | 4.1M | —Held | Q1 2026 | |
| 2 | BVF INC/IL | $50.5M | 2.7M | —Held | Q1 2026 | |
| 3 | Fairmount Funds Management LLC | $49.5M | 2.7M | —Held | Q2 2026 | |
| 4 | Venrock Adviser, LLC | $39.2M | 2.1M | —Held | Q1 2026 | |
| 5 | FCPM III SERVICES B.V. | $30.2M | 1.7M | —Held | Q2 2026 | |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | $27.7M | 1.5M | ▲14× Added · +1.4M sh | Q1 2026 | |
| 7 | Vestal Point Capital, LP | $27.6M | 1.5M | —Held | Q1 2026 | |
| 8 | Opaleye Management Inc. | $24.1M | 1.3M | ▲+11% Added · +134K sh | Q1 2026 | |
| 9 | TANG CAPITAL MANAGEMENT LLC | $21.3M | 1.2M | ▲+33% Added · +288K sh | Q1 2026 | |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | $14.7M | 801K | →First observed position No prior filed position | Q1 2026 | |
| 11 | Logos Global Management LP | $8.9M | 483K | ▼−20% Reduced · −118K sh | Q1 2026 | |
| 12 | Deep Track Capital, LP | $8.3M | 454K | —Held | Q1 2026 | |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | $6.9M | 385K | ▲+269% Added · +280K sh | Q2 2026 | |
| 14 | RTW INVESTMENTS, LP | $6.7M | 373K | —Held | Q2 2026 | |
| 15 | Remedium Capital Partners, LLC | $6.5M | 361K | ▲New +361K sh | Q2 2026 | |
| 16 | MILLENNIUM MANAGEMENT LLC | $5.9M | 324K | ▲+423% Added · +262K sh | Q1 2026 | |
| 17 | STATE STREET CORP | $5.7M | 316K | ▲+708% Added · +277K sh | Q2 2026 | |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | $5.6M | 304K | ▼−10% Reduced · −35K sh | Q1 2026 | |
| 19 | Point72 Asset Management, L.P. | $5.5M | 300K | —Held | Q1 2026 | |
| 20 | Alyeska Investment Group, L.P. | $4.8M | 264K | —Held | Q1 2026 | |
| 21 | GOLDMAN SACHS GROUP INC | $4.2M | 228K | ▲+805% Added · +203K sh | Q1 2026 | |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.9M | 214K | ▲+274% Added · +157K sh | Q1 2026 | |
| 23 | PERCEPTIVE ADVISORS LLC | $3.8M | 207K | ▼−54% Reduced · −247K sh | Q1 2026 | |
| 24 | MARSHALL WACE, LLP | $3.7M | 201K | ▲+820% Added · +179K sh | Q1 2026 | |
| 25 | Exome Asset Management LLC | $2.8M | 153K | ▲New +153K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 12 funds opened a new position in CBIO and 6 added to an existing one, while 8 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| COGENT BIOSCIENCES INCCOGT | 28 funds | $962.2M |
| REVOLUTION MEDICINES INCRVMD | 26 funds | $1.8B |
| CYTOKINETICS INCCYTK | 25 funds | $828.1M |
| UNITEDHEALTH GROUP INCUNH | 24 funds | $7.9B |
| APOGEE THERAPEUTICS INCAPGE | 24 funds | $1.4B |
| BOSTON SCIENTIFIC CORPBSX | 23 funds | $2.3B |
| ERASCA INCERAS | 23 funds | $1.0B |
| BIOGEN INCBIIB | 23 funds | $759.1M |
| RHYTHM PHARMACEUTICALS INCRYTM | 23 funds | $694.6M |
| VIRIDIAN THERAPEUTICS INCVRDN | 23 funds | $404.7M |
| MAZE THERAPEUTICS INCMAZE | 23 funds | $251.3M |
| NVIDIA CORPNVDA | 22 funds | $89.9B |
Ranked by how many of CBIO's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Buy (P) | 853K | $12.4M |
| Jun 22, 2026 | McNeill Jonathan | President and COO | Sell (S) | 21K | $370K |
| Jun 22, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell (S) | 1K | $22K |
| Jun 22, 2026 | Scalzo Richard William | Chief Financial Officer | Sell (S) | 1K | $20K |
| Jun 22, 2026 | Pinkas Jan | Chief Scientific Officer | Sell (S) | 1K | $23K |
| Jun 22, 2026 | Lynch Ryan | See Remarks | Sell (S) | 465 | $8K |
| Jun 22, 2026 | Bispham Barbara Harlin | See Remarks | Sell (S) | 1K | $22K |
| Jun 22, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sell (S) | 42K | $761K |
| Dec 4, 2025 | Harwin Peter Evan | Director, 10% Owner | Buy (P) | 1.4M | $18.2M |
| Aug 9, 2022 | Blouse Grant E. | Chief Scientific Officer | Buy (P) | 3K | $2K |
| Aug 9, 2022 | Miller Seline E. | SVP Finance; Interim CFO & PAO | Buy (P) | 3K | $2K |
| Aug 9, 2022 | USMAN NASSIM | President & CEO, Director | Buy (P) | 3K | $2K |
Connected entities for CBIO
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/CBIO/capital-change-brief"
Use Arkolith's capital_change_brief for CBIO. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for CBIO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.